top of page
ABOUT
AUTOIMMUNITY BIOSOLUTIONS
ABOUT
Next-Generation, Immuno-Corrective Therapy for Treatment of Autoimmune Diseases by Targeting a Novel, Fundamental Autoimmune Pathway Driven by Upregulation of the Soluble Interleukin 7 Receptor (sIL7R).
Autoimmunity BioSolutions (ABS) is developing a next-generation, immuno-corrective therapy to restore normal immune function in a genetically-defined subpopulation of autoimmune disease patients in which the autoimmune pathology is driven by a SNP that enhances the expression of sIL7R.
OUR VISION
First-Line Treatment for the Genetically-Defined Risk Population in Multiple Autoimmune Diseases.
ABS’ anti-sIL7R therapy is being developed as a first-line treatment for patients of various autoimmune diseases defined by the presence of the SNP and high levels of sIL7R.
OUR MISSION
Delivering this Immuno-Corrective Therapy to Patients in Great Need of Improved Treatments.
ABS is committed to provide patients with an effective immuno-corrective therapy that bypasses the safety liabilities associated with immunosuppression.
bottom of page